Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

May 11, 2017 Group News
evs-msc

The Cell Factory expands its patent portfolio on extracellular vesicles biologic drugs in China.

Esperite’s (Euronext: ESP) biotech company The Cell Factory has obtained the patent for use of extracellular vesicles (EVs) in treatment of acute and chronic inflammatory and autoimmune diseases in China. This allows The Cell Factory entering into one of the largest markets of advanced therapeutics with its disruptive technology of the extracellular vesicles products replacing allogenic MSCs therapies. The Cell Factory will be presenting its EVs products: CF-MEV-107 for treatment of Crohn’s disease and CF-MEV-117 for treatment of drug resistant epilepsy during ChinaBio Partnering Forum 2017 in Zhuhai, China from May 31-June 1, 2017.

Zutphen, The Netherlands – 11 May 2017

read more

Esperite (ESP), The Cell Factory demonstrate antiinflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

May 5, 2017 Group News
immunology

CF-MEV-117 drug development confirming an anti-inflammatory and immunosuppressive activity of the CF-MEV-117 in a dose response manner. Full results will be presented during the International Society for Extracellular Vesicles (ISEV) meeting in Toronto, Canada from 18-21 May, 2017.

Zutphen, The Netherlands – 5 May 2017

read more

EN – ESPERITE financial results for 2014 published, metamorphosis completed, first positive forecast growth at €36mio Revenues (+30%) for 2015

March 17, 2015 Financial Reports , Group News
esperite_financial _summary_2014_teaser

ESPERITE (“Esperite N.V. (Euronext: ESP, “ESPERITE” or “the Company”) strengthens market position of Genoma with acquisitions of exclusive technologies for fully-certified groundbreaking genetic tests.

Stem cell historical CryoSave’s core business now profitable and improving.

Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results.

Zutphen, The Netherlands – 17 March 2015

read more

FR – Publication des résultats financiers 2014 de ESPERITE, métamorphose terminée, première prévision de croissance positive des revenus à 36 millions € (+30%) pour 2015

March 17, 2015 Financial Reports , Group News

ESPERITE (Esperite NV, (Euronext : ESP) « Esperite » ou « la Société ») renforce le positionnement de Genoma sur le marché par des acquisitions de technologies exclusives pour la réalisation de tests génétiques révolutionnaires entièrement certifiés.

Le coeur de métier historique de CryoSave dans les cellules souches est maintenant rentable et en constante amélioration.

Opérations consolidées, effectifs rationalisés, stratégies vente et marketing alignées, laboratoires intégrés, et processus automatisés pour l’obtention de meilleures performances et résultats.

Zutphen, Hollande – 17 Mars 2015

read more